GERMANTOWN, Md., Jan. 2, 2019 /PRNewswire/ -- Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced that the company and its subsidiaries will present at upcoming investor conferences in San Francisco.
- Pieter Rottiers, PhD, Chief Executive Officer of ActoBio Therapeutics, will present at the Biotech Showcase on January 8th, 2019 at 9:00 AM PT at the Hilton San Francisco Union Square.
- Thomas D. Reed, PhD, Chief Science Officer of Intrexon and Amit Patel, MD, Founder of Xogenex, will present at the Biotech Showcase on January 9th, 2019 at 8:45 AM PT at the Hilton San Francisco Union Square.
- Randal J. Kirk, Chairman and Chief Executive Officer of Intrexon, will present at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9th, 2019 at 11:30 AM PT at the Westin St. Francis Hotel. A live webcast of the presentation will be available on the Investors section of Intrexon's website at https://investors.dna.com/events, and a replay of the webcast will be available for 30 days following the event.
Additionally, as previously announced, Helen Sabzevari, PhD, President of Precigen, will be presenting a first-look at Precigen's preclinical and clinical portfolio at an investor event Monday, January 7, 2019 at 3:00pm PT. The presentation will be available via live audio webcast through Intrexon's website at https://investors.dna.com/events. Spaces are available for individuals who would like to participate in-person at the onsite event. For in-person participation, RSVP is required, and all RSVPs must be received at firstname.lastname@example.org by January 6, 2019 at 5:00 pm PT.
About Intrexon Corporation
Intrexon Corporation (NASDAQ: XON) is Powering the Bioindustrial Revolution with Better DNA™ to create biologically-based products that improve the quality of life and the health of the planet. Intrexon's integrated technology suite provides its partners across diverse markets with industrial-scale design and development of complex biological systems delivering unprecedented control, quality, function, and performance of living cells. We call our synthetic biology approach Better DNA®, and we invite you to discover more at www.dna.com or follow us on Twitter at @Intrexon, on Facebook, and LinkedIn.
Intrexon, Powering the Bioindustrial Revolution with Better DNA, and Better DNA are trademarks of Intrexon and/or its affiliates. Other names may be trademarks of their respective owners.
Safe Harbor Statement
Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release.
For more information regarding Intrexon Corporation, contact:
SOURCE Intrexon Corporation